Ignite Creation Date:
2024-05-05 @ 5:09 PM
Last Modification Date:
2024-10-26 @ 9:28 AM
Study NCT ID:
NCT00392691
Status:
COMPLETED
Last Update Posted:
2019-05-15
First Post:
2006-10-25
Brief Title:
Melphalan Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab Followed by Autologous Stem Cell Transplant in Treating Older Patients With Non-Hodgkins Lymphoma That Has Relapsed or Not Responded to Previous Treatment
Sponsor:
Swiss Group for Clinical Cancer Research
Organization:
Swiss Group for Clinical Cancer Research
Organization Data
Organization:
Swiss Group for Clinical Cancer Research
Class:
OTHER
Study ID:
SAKK 3705
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Swiss Group for Clinical Cancer Research
Lead Sponsor Class:
OTHER
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None